Medical device company Integra LifeSciences (NASDAQ: IART) missed Wall Street’s revenue expectations in Q3 CY2025, but sales rose 5.6% year on year to $402.1 million. Next quarter’s revenue guidance of $430 million underwhelmed, coming in 5.9% below analysts’ estimates. Its non-GAAP profit of $0.54 per share was 24.1% above analysts’ consensus estimates.

Is now the time to buy IART? Find out in our full research report (it’s free for active Edge members).

StockStory’s Take

Integra LifeSciences’ third quarter was marked by operational disruptions and underwhelming revenue growth, resulting in a significant negative market reaction. Management attributed the revenue shortfall to two supply interruptions in its Codman Specialty Surgical (CSS) business and insufficient inventory levels, which offset healthy demand across the company’s broader portfolio. CEO Mojdeh Poul noted, “Our third quarter revenue shortfall underscores the work still ahead to achieve greater execution consistency,” emphasizing the ongoing transformation needed in supply chain reliability and execution. Despite these challenges, the company delivered strong operating income and improved cash flow, driven by disciplined cost control and operational efficiencies.

Looking to the upcoming quarter and beyond, Integra LifeSciences’ guidance is shaped by continued supply chain investments, remediation efforts, and the phased return of key products. Management expects margin pressures from ongoing compliance and remediation costs, as well as tariffs, but believes its transformation initiatives will support long-term growth. CFO Lea Knight noted that while variability is likely as remediation progresses, the priorities of compliance, operational excellence, and financial discipline are expected to drive more consistent results. Poul added, “We will continue to balance near-term execution with investments that strengthen our foundation for sustainable growth.”

Key Insights from Management’s Remarks

Management believes execution on supply chain improvements and product relaunches is critical, while ongoing compliance costs and product mix shifts impacted near-term results.

• Supply chain transformation underway: Integra LifeSciences is investing in a foundational overhaul of its supply chain, led by new leadership and strategic dual sourcing agreements. This initiative, already resulting in a 50% manufacturing yield improvement for Integra Skin and increased inventory levels, aims to reduce future supply interruptions and enable more predictable growth.
• Product relaunches ahead of schedule: The company successfully reintroduced PriMatrix and Durepair almost a year earlier than expected via a new third-party supply agreement. Management sees this as a major step in restoring lost market share and meeting unmet demand from clinicians and patients.
• International and neurosurgery momentum: Strong growth in international markets—particularly China, which saw a 24% year-over-year increase—was fueled by renewed product availability and deeper market penetration. Within neurosurgery, leading products like Certas Plus, DuraGen, and CereLink drove outsized performance, benefiting from both strong end-market demand and favorable comparisons to last year.
• Portfolio prioritization and margin initiatives: A company-wide review led to a focus on higher-growth, more profitable product categories, with ongoing investments in clinical evidence and regulatory approvals for products like SurgiMend and DuraSorb. Concurrently, management’s margin expansion program targets $25–$30 million in cost reductions by 2026 through improvements in cost of goods sold (COGS), third-party spend, and operational efficiencies.
• Persistent headwinds in Tissue Technologies: While Integra Skin and DuraSorb posted robust growth, the MediHoney product line remained pressured due to ongoing remediation, and private label sales continued to be challenged by a key partner’s market share decline. These factors weighed on overall segment performance, partially offsetting gains elsewhere.

Drivers of Future Performance

Management expects supply chain stabilization, product relaunches, and continued investment in operational improvements to shape the company’s near-term trajectory.

• Ongoing compliance and remediation costs: Management signaled that investments in compliance initiatives and remediation efforts—particularly related to the Compliance Master Plan and supply chain—will continue to pressure gross margins in the near term. These costs are expected to decline over time as remediation phases complete, but remain a significant consideration for the next several quarters.
• Mixed recovery across product lines: The relaunch of PriMatrix and Durepair provides a path to recapture lost revenue, but management cautioned that regaining market share will take time. Meanwhile, headwinds persist in the private label and MediHoney segments, where recovery is heavily dependent on partner performance and successful remediation, respectively.
• International and high-growth category focus: Stronger supply and expanded international reach, especially in China and other strategic markets, are expected to support overall growth. Additionally, management’s focus on shifting the portfolio toward higher-growth, evidence-based categories such as implant-based breast reconstruction aims to improve profitability and resilience against cost pressures like tariffs.

Catalysts in Upcoming Quarters

Looking ahead, our analysts will track (1) the effectiveness of supply chain improvements, as measured by reduced product interruptions and inventory stability; (2) the pace of market share recovery from PriMatrix and Durepair relaunches; and (3) progress on key cost-saving initiatives and gross margin stabilization. We will also monitor international sales momentum and the resolution of ongoing headwinds in the private label and MediHoney segments.

Integra LifeSciences currently trades at $11.92, down from $15.43 just before the earnings. At this price, is it a buy or sell? Find out in our full research report (it’s free for active Edge members).

Now Could Be The Perfect Time To Invest In These Stocks

Trump’s April 2025 tariff bombshell triggered a massive market selloff, but stocks have since staged an impressive recovery, leaving those who panic sold on the sidelines.

Take advantage of the rebound by checking out our Top 5 Strong Momentum Stocks for this week. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025).

Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-small-cap company Exlservice (+354% five-year return). Find your next big winner with StockStory today.

StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here.